Brought to you by 
GSK and Myogen sign two PAH agreements
Mar 2006
Executive Summary
Myogen (develops small molecules for cardiovascular diseases) licensed GlaxoSmithKline ex-US commercialization rights to the Phase III pulmonary arterial hypertension (PAH) compound ambrisentan. Concurrently, GSK has licensed Myogen US marketing and distribution rights to sell its PAH drug Flolan (epoprostenol) for three years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Product or Technology Swap
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK and Myogen sign two PAH agreements
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice